Teriparatide Accelerates Lumbar Posterolateral Fusion in Women With Postmenopausal Osteoporosis
Authors:
- Seiji OhtoriSOSeiji Ohtori
- Gen InoueGIGen Inoue
- Sumihisa OritaSOSumihisa Orita
- Kazuyo YamauchiKYKazuyo Yamauchi
- Yawara EguchiYEYawara Eguchi
- Nobuyasu OchiaiNONobuyasu Ochiai
- Shunji KishidaSKShunji Kishida
- Kazuki KuniyoshiKKKazuki Kuniyoshi
- Yasuchika AokiYAYasuchika Aoki
- Junichi NakamuraJNJunichi Nakamura
- Tetsuhiro IshikawaTITetsuhiro Ishikawa
- Masayuki MiyagiMMMasayuki Miyagi
- 1 November 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Spine
- Vol. 37 (23) , E1464-E1468
Abstract
Prospective trial. To examine the clinical efficacy of teriparatide for bone union after instrumented lumbar posterolateral fusion using local bone grafting in women with postmenopausal osteoporosis. Intermittent parathyroid hormone (PTH) treatment increases bone mass and reduces the risk for osteoporotic vertebral fractures. Recombinant human PTH (1–34) has already been approved as a treatment for severe osteoporosis. Preclinical data support the efficacy of PTH for lumbar spinal fusion. However, clinical results of PTH for spinal fusion have not yet been reported. Fifty-seven women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 2 treatment groups, a teriparatide group (n = 29; daily subcutaneous injection of 20 μg of teriparatide) and a bisphosphonate group (n = 28; weekly oral administration of 17.5 mg of risedronate). All patients underwent decompression and 1- or 2-level instrumented posterolateral fusion with a local bone graft. Fusion rate, duration of bone union, and pain scores were evaluated 1 year after surgery. Pain scores improved after surgery; however, no significant difference was noted between the groups after surgery. The rate of bone union was 82% in the teriparatide group and 68% in the bisphosphonate group. Average duration of bone union was 8 months in the teriparatide group and 10 months in the bisphosphonate group. The rate of bone union and average of duration of bone union in the teriparatide group patients were significantly superior to those in the bisphosphonate group. Daily subcutaneous injection of teriparatide for bone union using local bone grafting after instrumented lumbar posterolateral fusion in women with postmenopausal osteoporosis was more effective than oral administration of bisphosphonate.Keywords
This publication has 19 references indexed in Scilit:
- Effect of Teriparatide [rhPTH(1,34)] and Calcitonin on Intertransverse Process Fusion in a Rabbit ModelSpine, 2010
- An update on bone substitutes for spinal fusionEuropean Spine Journal, 2009
- Effects of Age and Comorbidities on Complication Rates and Adverse Outcomes After Lumbar Laminectomy in Elderly PatientsSpine, 2008
- Pseudarthrosis in Long Adult Spinal Deformity Instrumentation and Fusion to the Sacrum: Prevalence and Risk Factor Analysis of 144 CasesSpine, 2006
- Iliac Crest Bone Graft Donor Site Pain After Anterior Lumbar Interbody FusionJournal of Spinal Disorders & Techniques, 2005
- Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy StudyJournal of Bone and Mineral Research, 2001
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Chronic Donor Site Pain Complicating Bone Graft Harvesting From the Posterior Iliac Crest for Spinal FusionSpine, 1992
- Harvesting Autogenous Iliac Bone GraftsSpine, 1989
- Morbidity at Bone Graft Donor SitesJournal of Orthopaedic Trauma, 1989